Figure A1 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Year: 2023
Type: other
Abstract: Figure A1 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Authors: David A. Reardon, Annick Desjardins, James J. Vredenburgh, Donald M. O'Rourke, David D. Tran, Karen L. Fink, Louis B. Nabors, Gordon Li, Daniela A. Bota, Rimas V. Lukas, Lynn S. Ashby, J. Paul Duic, Maciej M. Mrugala, Scott Cruickshank, Laura Vitale, Yi He, Jennifer A. Green, Michael J. Yellin, Christopher D. Turner, Tibor Keler, Thomas A. Davis, John H. Sampson
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361936115